FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacynews2024-11-07T17:02:53+00:00November 7th, 2024|Endpoints News|
Coherus restarts biosimilar supply after delays; Novavax ends Covid vaccine deal with UKnews2024-11-07T16:45:15+00:00November 7th, 2024|Endpoints News|
Genmab chops early cancer prospects to prioritize Phase 3 projectsnews2024-11-07T16:21:56+00:00November 7th, 2024|Endpoints News|
Aurinia cuts nearly half of its workforce in second round of layoffs this yearnews2024-11-07T16:18:12+00:00November 7th, 2024|Endpoints News|
Geron’s royalty deal; Minghui’s new VEGF bispecific datanews2024-11-07T15:53:28+00:00November 7th, 2024|Endpoints News|
Denali teases early data for enzyme replacement therapy in rare diseasenews2024-11-07T14:49:55+00:00November 7th, 2024|Endpoints News|
Nobel winner Demis Hassabis talks next steps for AI in biologynews2024-11-07T14:00:37+00:00November 7th, 2024|Endpoints News|
Avid Bioservices to be sold to private equity firms for $1.1Bnews2024-11-07T13:29:18+00:00November 7th, 2024|Endpoints News|
How Menlo Ventures thinks AI in health tech is going to be commoditizednews2024-11-07T13:16:28+00:00November 7th, 2024|Endpoints News|
Gilead beats Covid drug sales forecasts, takes $1.75B hit on Trodelvy study failnews2024-11-07T12:27:53+00:00November 7th, 2024|Endpoints News|
